GGrantIndex
← Leaderboards

Gianpietro Dotti

Univ Of North Carolina Chapel Hill

Google Scholar ↗PubMed ↗ORCID ↗
$17,018,250
Attributed
$18,363,846
Total exposure
12
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY2007–25
$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,363,846 · 12

By mechanism

R01$11,428,182 · 5
P50$4,975,101 · 3
P01$1,365,353 · 1
R21$372,034 · 1
R03$176,005 · 1
P30$47,171 · 1

Top collaborators

Most similar at Univ Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Tumor”

Research focus

TumorT-LymphocyteCellsAntigensImmuneResponseNeoplastic CellChimeric Antigen ReceptorB Lymphoid MalignancyEngineeringImmunotherapyB-LymphocytesSafetyIn VivoPhase I Clinical TrialsInfusion ProceduresPre-Clinical ModelCd19 GeneAntigen TargetingCd19 AntigensT Cell TherapyMouse ModelRelapseSignal Transduction

Grant awards (51)

Targeting B7-H3 in ovarian cancer$597,170
R01 · FY2025 · CA · contact PI
Tuning CAR-T cell function$496,990
R01 · FY2025 · CA · contact PI
Project 2: Combined CAR-T cell therapy$447,559
P50 · FY2025 · CA · contact PI
Project 4: Activity of CAR T cell Therapy for Patients with Metastatic TNBC$365,428
P50 · FY2025 · CA · contact PI
Immunology Research Program$47,171
P30 · FY2025 · CA · contact PI
Targeting B7-H3 in ovarian cancer$556,817
R01 · FY2024 · CA · contact PI
Tuning CAR-T cell function$472,143
R01 · FY2024 · CA · contact PI
Project 2: Combined CAR-T cell therapy$429,640
P50 · FY2024 · CA · contact PI
Project 4: Activity of CAR T cell Therapy for Patients with Metastatic TNBC$356,676
P50 · FY2024 · CA · contact PI
Tuning CAR-T cell function$487,050
R01 · FY2023 · CA · contact PI
Project 2: Combined CAR-T cell therapy$483,710
P50 · FY2023 · CA · contact PI
Cellular Immunotherapy of Ovarian Cancer$387,206
R01 · FY2023 · CA · contact PI
Targeting B7-H3 in ovarian cancer$109,227
R01 · FY2023 · CA · contact PI
Targeting B7-H3 in ovarian cancer$619,664
R01 · FY2022 · CA · contact PI
Tuning CAR-T cell function$487,050
R01 · FY2022 · CA · contact PI
Project 2: Combined CAR-T cell therapy$433,764
P50 · FY2022 · CA · contact PI
Cellular Immunotherapy of Ovarian Cancer$387,206
R01 · FY2022 · CA · contact PI
Targeting B7-H3 in ovarian cancer$632,310
R01 · FY2021 · CA · contact PI
Tuning CAR-T cell function$496,990
R01 · FY2021 · CA · contact PI
Cellular Immunotherapy of Ovarian Cancer$395,109
R01 · FY2021 · CA · contact PI
Targeting the Ig-light chains with CAR-T cells in lymphoid tumors$542,644
R01 · FY2020 · CA · contact PI
Cellular Immunotherapy of Ovarian Cancer$395,109
R01 · FY2020 · CA · contact PI
Targeting and Delivering CAR-Ts in Glioblastoma$169,106
R21 · FY2020 · CA · contact PI
Targeting the Ig-light chains with CAR-T cells in lymphoid tumors$554,685
R01 · FY2019 · CA · contact PI
Cellular Immunotherapy of Ovarian Cancer$401,407
R01 · FY2019 · CA · contact PI
Targeting and Delivering CAR-Ts in Glioblastoma$202,928
R21 · FY2019 · CA · contact PI
Safety and anti-tumor activity of B7-H3 CAR T cells in TNBC$79,286
R03 · FY2019 · CA
Targeting the Ig-light chains with CAR-T cells in lymphoid tumors$511,190
R01 · FY2018 · CA · contact PI
Safety and anti-tumor activity of B7-H3 CAR T cells in TNBC$96,719
R03 · FY2018 · CA
Targeting the Ig-light chains with CAR-T cells in lymphoid tumors$569,255
R01 · FY2017 · CA · contact PI
Targeting the Ig-light chains with CAR-T cells in lymphoid tumors$569,255
R01 · FY2016 · CA · contact PI
CHIMERIC T CELL ANTIGENS TARGETING IG KAPPA LIGHT CHAIN IN B CELL LYMPHOMA$220,316
P50 · FY2016 · CA · contact PI
CD19-Specific CB T-cell Therapy for Patients with B-cell Malignancies$46,051
P01 · FY2016 · CA · contact PI
CD19-Specific CB T-cell Therapy for Patients with B-cell Malignancies$395,087
P01 · FY2015 · CA · contact PI
CHIMERIC T CELL ANTIGENS TARGETING IG KAPPA LIGHT CHAIN IN B CELL LYMPHOMA$222,662
P50 · FY2015 · CA · contact PI
Improving T-cell therapies for neuroblastoma$287,576
R01 · FY2014 · CA · contact PI
CHIMERIC T CELL ANTIGENS TARGETING IG KAPPA LIGHT CHAIN IN B CELL LYMPHOMA$220,318
P50 · FY2014 · CA · contact PI
CD19-Specific CB T-cell Therapy for Patients with B-cell Malignancies$153,538
P01 · FY2014 · CA · contact PI
Improving T-cell therapies for neuroblastoma$366,494
R01 · FY2013 · CA · contact PI
CD19-Specific CB T-cell Therapy for Patients with B-cell Malignancies$357,151
P01 · FY2013 · CA · contact PI
CHIMERIC T CELL ANTIGENS TARGETING IG KAPPA LIGHT CHAIN IN B CELL LYMPHOMA$220,788
P50 · FY2013 · CA · contact PI
CD19-Specific CB T-cell Therapy for Patients with B-cell Malignancies$413,526
P01 · FY2012 · CA · contact PI
Improving T-cell therapies for neuroblastoma$377,399
R01 · FY2012 · CA · contact PI
CHIMERIC T CELL ANTIGENS TARGETING IG KAPPA LIGHT CHAIN IN B CELL LYMPHOMA$234,380
P50 · FY2012 · CA · contact PI
Improving T-cell therapies for neuroblastoma$447,592
R01 · FY2011 · CA · contact PI
Chimeric T Cell Antigens Targeting Kappa in B Cell Lymphoma$244,600
P50 · FY2011 · CA · contact PI
Chimeric T Cell Antigens Targeting Kappa in B Cell Lymphoma$295,842
P50 · FY2010 · CA · contact PI
Improving T-cell therapies for neuroblastoma$280,644
R01 · FY2010 · CA · contact PI
Chimeric T Cell Antigens Targeting Kappa in B Cell Lymphoma$299,207
P50 · FY2009 · CA · contact PI
Chimeric T Cell Antigens Targeting Kappa in B Cell Lymphoma$256,857
P50 · FY2008 · CA · contact PI
Chimeric T Cell Antigens Targeting Kappa in B Cell Lymphoma$243,354
P50 · FY2007 · CA · contact PI